Skip to main content
SpringerLink
Log in

Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol

  • Hypertension and Metabolic Syndrome (J Sperati, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Blood pressure management in hypertensive patients with metabolic abnormalities is challenging, since many of the antihypertensive drugs adversely affect metabolism. Besides effective control of blood pressure in patients with hypertension, third-generation beta-blockers such as nebivolol offer additional benefits for central hemodynamics and neutral or beneficial effects on metabolism. Emerging clinical data suggest that nebivolol also has similar effects on metabolism in obese hypertensive and hypertensive diabetic patients. The present article will provide a systematic analysis of the pathophysiological links among hypertension, insulin resistance, and metabolic syndrome. We will also summarize the available clinical evidence regarding the metabolic effects of beta-blockers in hypertensive patients, with an emphasis on nebivolol. Nebivolol exerts neutral or beneficial effects on insulin sensitivity and lipid metabolism in hypertensive patients, owing to its nitric oxide-mediated vasodilatory and antioxidative properties. Thus, nebivolol could be a favorable therapeutic option for the treatment of hypertension in patients with impaired glucose and lipid metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014;6:517–30.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mulè G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: an unholy alliance. World J Cardiol. 2014;6:890–907.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491–9.

    Article  PubMed  Google Scholar 

  4. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol. 1988;34:843–51.

    CAS  PubMed  Google Scholar 

  5. Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753–7.

    Article  CAS  PubMed  Google Scholar 

  6. Pesant Y, Marc-Aurele J, Bielmann P, Alaupovic P, Cartier P, Bichet D, et al. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther. 1999;6:137–47.

    Article  CAS  PubMed  Google Scholar 

  7. Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–35.

    Article  CAS  PubMed  Google Scholar 

  8. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8:127–34.

    Article  CAS  PubMed  Google Scholar 

  9. •• Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591–6. A prospective, blinded, randomized study highlighting that nebivolol, in contrast to metoprolol, improved oxidative stress, insulin sensitivity, decreased plasma soluble P-selectin and increased adiponectin levels in hypertensive patients.

    Article  CAS  PubMed  Google Scholar 

  10. Peter P, Martin U, Sharma A, Dunne F. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther. 2006;31:153–9.

    Article  CAS  PubMed  Google Scholar 

  11. Schulman IH, Zhou MS. Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep. 2009;11:48–55.

    Article  CAS  PubMed  Google Scholar 

  12. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens. 2010;28:527–35.

    Article  CAS  PubMed  Google Scholar 

  13. Wu G, Meininger CJ. Nitric oxide and vascular insulin resistance. Biofactors. 2009;35:21–7.

    Article  PubMed  Google Scholar 

  14. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45:623–34.

    Article  CAS  PubMed  Google Scholar 

  15. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127–33.

    Article  CAS  PubMed  Google Scholar 

  16. Jacob S, Henriksen EJ. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich). 2004;6:690–6. quiz 697.

    Article  CAS  Google Scholar 

  17. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75:809–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Salvetti A, Brogi G, Di Legge V, Bernini GP. The inter-relationship between insulin resistance and hypertension. Drugs. 1993;46 Suppl 2:149–59.

    Article  PubMed  Google Scholar 

  19. Cheung BMY, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14:160–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. NCEP. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.

    Google Scholar 

  21. Mulè G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich). 2006;8:195–201.

    Article  Google Scholar 

  22. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–78.

    Article  PubMed  Google Scholar 

  23. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7.

    Article  CAS  PubMed  Google Scholar 

  24. Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817–22.

    Article  PubMed  Google Scholar 

  25. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.

    Article  PubMed  Google Scholar 

  26. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

    Article  PubMed  Google Scholar 

  27. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res. 2007;101:27–39.

    Article  CAS  PubMed  Google Scholar 

  28. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens. 2008;26:1891–900.

    Article  CAS  PubMed  Google Scholar 

  30. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7.

    Article  CAS  PubMed  Google Scholar 

  31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.

    Article  CAS  PubMed  Google Scholar 

  32. Navare HA, Frye RF, Cooper-Dehoff RM, Shuster JJ, Hall K, Schmidt SO, et al. Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. Pharmacotherapy. 2010;30:872–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431–6.

    Article  CAS  PubMed  Google Scholar 

  34. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250–4.

    Article  CAS  PubMed  Google Scholar 

  35. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.

    Article  CAS  PubMed  Google Scholar 

  36. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006;2:303–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955–9.

    Article  CAS  PubMed  Google Scholar 

  38. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489–94.

    Article  CAS  PubMed  Google Scholar 

  39. Owada A, Suda S, Hata T, Miyake S. The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens. 2001;23:305–16.

    Article  CAS  PubMed  Google Scholar 

  40. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386–93.

    Article  PubMed  Google Scholar 

  41. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19:667–74.

    Article  CAS  PubMed  Google Scholar 

  42. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord. 1998;22:39–47.

    Article  CAS  PubMed  Google Scholar 

  43. Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am J Epidemiol. 1984;119:526–40.

    Article  CAS  PubMed  Google Scholar 

  44. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension. 2004;44:127–33.

    Article  CAS  PubMed  Google Scholar 

  45. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J. Hazards of obesity—the Framingham experience. Acta Med Scand Suppl. 1998;723:23–36.

    Google Scholar 

  46. Leren P. Effects of antihypertensive drugs on lipid metabolism. Clin Ther. 1987;9:326–32.

    CAS  PubMed  Google Scholar 

  47. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation. 1960;21:21–7.

    Article  CAS  PubMed  Google Scholar 

  48. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol. 1991;67:26B–35.

    Article  CAS  PubMed  Google Scholar 

  49. Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs. 1998;35 Suppl 6:118–34.

    Google Scholar 

  50. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:309–15.

    Article  CAS  Google Scholar 

  51. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, et al. GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120:610–5.

    Article  CAS  PubMed  Google Scholar 

  52. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009;11:234–8.

    Article  CAS  PubMed  Google Scholar 

  53. Hauf-Zachariou U, Widmann L, Zülsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol. 1993;45:95–100.

    Article  CAS  PubMed  Google Scholar 

  54. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67:1097–107.

    Article  PubMed  Google Scholar 

  55. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology. 2006;106:199–206.

    Article  CAS  PubMed  Google Scholar 

  56. • Marazzi G, Volterrani M, Caminiti G, Iaia L, Cacciotti L, Massaro R, et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther. 2010;27:655–64. This study indicates that the addition of hydrochlorothiazide on nebivolol treatment optimizes blood pressure control in a high number of patients resistant to monotherapy without a negative impact on patients’ glucose and lipid profile.

    Article  CAS  PubMed  Google Scholar 

  57. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–904.

    Article  PubMed  Google Scholar 

  59. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, et al. Endothelial beta 3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198–205.

    Article  CAS  PubMed  Google Scholar 

  60. Kiso T, Namikawa T, Tokunaga T, Sawada K, Kakita T, Shogaki T, et al. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice. Biol Pharm Bull. 1999;22:1073–8.

    Article  CAS  PubMed  Google Scholar 

  61. de Souza CJ, Burkey BF. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001;7:1433–49.

    Article  PubMed  Google Scholar 

  62. Merchant N, Rahman ST, Ferdinand KC, Haque T, Umpierrez GE, Khan BV. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens. 2011;25:196–202.

    Article  CAS  PubMed  Google Scholar 

  63. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27:841–9.

    Article  CAS  PubMed  Google Scholar 

  64. • Van Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. Eur Rev Med Pharmacol Sci. 2010;14:749–58. A surveillance study showing that nebivolol treatment is associated with a significantly reduced BP, improved blood glucose and LDL cholesterol levels and is well tolerated in hypertensive patients with concomitant diabetes.

    PubMed  Google Scholar 

  65. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397–403.

    Article  CAS  PubMed  Google Scholar 

  66. Malacco E. Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients. Eur Rev Med Pharmacol Sci. 2010;14:427–34.

    CAS  PubMed  Google Scholar 

  67. • Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens (Greenwich). 2013;15:270–8. A multicenter trial showing that nebivolol, added to an ACE inhibitor or ARB, provides additional blood pressure reduction with little or no effect on glucose metabolism in hypertensive patients with prediabetes.

    Article  CAS  Google Scholar 

  68. •• Ozyıldız AG, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H. Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther. 2016. A prospective, randomized study indicating the favourable effects of new generation b-blockers on glucose, insulin, insulin resistance, and the lipid profile.

  69. •• Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893–8. A comparative study indicating that treatment with metoprolol decreased insulin sensitivity and increased oxidative stress and the antifibrinolytic plasminogen activator inhibitor 1 in patients with metabolic syndrome, whereas nebivolol lacked detrimental metabolic effects.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. ••Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol. 2010;56:275–81. A large study in five thousand thirty-one male and female patients indicating that nebivolol is effective in treating patients with diabetes suffering from high blood pressure and metabolic syndrome.

    Article  CAS  PubMed  Google Scholar 

  71. Lacourcière Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660–6.

    Article  PubMed  Google Scholar 

  72. Predel HG, Mainka W, Schillings W, Knigge H, Montiel J, Fallois J, et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens. 2001;15:715–21.

    Article  CAS  PubMed  Google Scholar 

  73. Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007;3:647–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–8.

    Article  CAS  PubMed  Google Scholar 

  75. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5:353–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Rubattu S, Pagliaro B, Pierelli G, et al. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2014;16:823–39.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634–40.

    Article  CAS  PubMed  Google Scholar 

  78. Mustone Alexander L. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs. 2006;66:1239–52.

    Article  PubMed  Google Scholar 

  79. Ladage D, Reidenbach C, Lichtenthal A, Schwinger R, Brixius K. Third generation betablockers: current state of research on vasodilating beta-blockers. Wien Med Wochenschr. 2009;159:211–8.

    Article  PubMed  Google Scholar 

  80. Vinker S, Alkalay A, Hoffman RD, Elhayany A, Kaiserman I, Kitai E. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin Pharmacother. 2008;9:1271–7.

    Article  PubMed  Google Scholar 

  81. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther. 2011;33:1150–61.

    Article  CAS  PubMed  Google Scholar 

  82. • Bhosale VV, Inamdar SC, Karande VB, Burute SR, Murthy MB, Ghatak A. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res. 2014;8:HC01–4. A prospective, double blind, comparative controlled clinical study highlighting the superior efficacy and safety of nebivolol compared to atenolol.

    PubMed  PubMed Central  Google Scholar 

  83. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866–75.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Editorial support for the preparation of this manuscript was provided by the SPRIM Company, Singapore, through an unrestricted educational grant by A. Menarini.

Author information

Authors and Affiliations

  1. Cardiology Department, Heraklion University Hospital, P.O. Box 1352, Stavrakia, Heraklion, Crete, Greece

    Maria Marketou & Panos Vardas

  2. SPRIM Asia-Pacific Pvt. Ltd., Singapore, Singapore

    Yashaswi Gupta & Shashank Jain

Authors
  1. Maria Marketou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yashaswi Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shashank Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Panos Vardas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panos Vardas.

Ethics declarations

Conflict of Interest

Drs. Marketou, Gupta, and Vardas declare no conflicts of interest relevant to this manuscript. Dr. Jain reports grants from A. Manarini, Singapore, and support from SPRIM Asia Pacific Ltd, Singapore.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and Metabolic Syndrome

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marketou, M., Gupta, Y., Jain, S. et al. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol. Curr Hypertens Rep 19, 22 (2017). https://doi.org/10.1007/s11906-017-0716-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0716-3

Keywords

Search

Navigation